Table 1.
Basic Characteristics | All Participants (n = 65) |
Participants with Sequences Generated (n = 34) | |
---|---|---|---|
* Age (years), median (Q1, Q3) | 40 (27, 49) | 41 (26, 45) | |
Gender | Female n (%) | 37 (57%) | 15 (44%) |
Male n (%) | 28 (43%) | 19 (56%) | |
Median log 10 HIV-1 VL (Q1, Q3) copies/mL | † 3.78 (2.13, 4.49) | ± 4.53 (3.98, 5.10) |
N.B; VL was measured from all plasma samples sent for GRT before commencing testing as per standard of care. † VL written as <20, <400 or <40 or TND, we used 20, 400, 40 and 20 respectively for analysis. In this analysis they were nine out of 65. * 6 individuals did not have age written on the requisition and could not calculate their age.; they are not included in the analysis of age. †± VL was from 35 of the 40 plasma samples at the time of GRT as 5 had UNK VLs. cART, combination antiretroviral therapy; DTG, dolutegravir; RAL, raltegravir; VL, viral load, UNK, unknown; TND, target not detected.